JP2010510317A5 - - Google Patents

Download PDF

Info

Publication number
JP2010510317A5
JP2010510317A5 JP2009538461A JP2009538461A JP2010510317A5 JP 2010510317 A5 JP2010510317 A5 JP 2010510317A5 JP 2009538461 A JP2009538461 A JP 2009538461A JP 2009538461 A JP2009538461 A JP 2009538461A JP 2010510317 A5 JP2010510317 A5 JP 2010510317A5
Authority
JP
Japan
Prior art keywords
agent
alkyl
aryl
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009538461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510317A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/084927 external-priority patent/WO2008064107A2/en
Publication of JP2010510317A publication Critical patent/JP2010510317A/ja
Publication of JP2010510317A5 publication Critical patent/JP2010510317A5/ja
Withdrawn legal-status Critical Current

Links

JP2009538461A 2006-11-20 2007-11-16 ジペプチジルペプチダーゼivの阻害剤としての7,8−ジヒドロ−1,6−ナフチリジン−5(6h)−オンおよび関連二環式化合物、および方法 Withdrawn JP2010510317A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86020206P 2006-11-20 2006-11-20
PCT/US2007/084927 WO2008064107A2 (en) 2006-11-20 2007-11-16 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods

Publications (2)

Publication Number Publication Date
JP2010510317A JP2010510317A (ja) 2010-04-02
JP2010510317A5 true JP2010510317A5 (enExample) 2010-12-16

Family

ID=39283892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009538461A Withdrawn JP2010510317A (ja) 2006-11-20 2007-11-16 ジペプチジルペプチダーゼivの阻害剤としての7,8−ジヒドロ−1,6−ナフチリジン−5(6h)−オンおよび関連二環式化合物、および方法

Country Status (8)

Country Link
US (1) US7723355B2 (enExample)
EP (1) EP2086975B1 (enExample)
JP (1) JP2010510317A (enExample)
CN (1) CN101595109B (enExample)
AT (1) ATE549334T1 (enExample)
ES (1) ES2382486T3 (enExample)
NO (1) NO20091938L (enExample)
WO (1) WO2008064107A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155367A0 (en) * 2000-10-23 2003-12-23 Smithkline Beecham Corp NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
JP2008537937A (ja) * 2005-03-25 2008-10-02 グラクソ グループ リミテッド ピリド[2,3−d]ピリミジン−7−オンおよび3,4−ジヒドロピリミド[4,5−d]ピリミジン−2(1H)−オン誘導体の製造方法
PE20100737A1 (es) * 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2308847B1 (en) 2009-10-09 2014-04-02 EMC microcollections GmbH Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8477028B2 (en) * 2010-09-24 2013-07-02 T-Mobile Usa, Inc. Misplaced device recovery
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX2015001099A (es) * 2012-08-24 2015-04-08 Hoffmann La Roche Nuevos derivados biciclicos de piridina.
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
CN104548096B (zh) * 2013-10-09 2019-09-10 深圳翰宇药业股份有限公司 一种含有glp-1类似物和dpp-4抑制剂的药物组合物及其制备方法
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
JP2025509672A (ja) 2022-03-17 2025-04-11 インサイト・コーポレイション Jak2 v617f阻害剤としての三環式尿素化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900224B2 (en) * 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
AU2003249531A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
GB0413389D0 (en) 2004-06-16 2004-07-21 Astrazeneca Ab Chemical compounds
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
GB0420970D0 (en) * 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
WO2006065842A2 (en) * 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2010510317A5 (enExample)
JP2011512352A5 (enExample)
JP2007512370A5 (enExample)
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
JP2011519374A5 (enExample)
JP2013040219A5 (enExample)
JP2008526869A5 (enExample)
JP2011515398A5 (enExample)
JP2011520792A5 (enExample)
JP2012516871A5 (enExample)
RU2008152763A (ru) Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии
RU2003117476A (ru) Аминотиазолы и их применение в качестве антагонистов рецептора аденозина
JP2013538235A5 (enExample)
RU2017144495A (ru) Противогельминтные депсипептидные соединения
JP2007533741A5 (ja) Bace阻害剤として有用なピロリジン誘導体
JP2007517035A5 (enExample)
JP2006524660A5 (enExample)
JP2010510233A5 (enExample)
JP2009532486A5 (enExample)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2018509418A5 (enExample)
JP2009502948A5 (enExample)
JP2014524472A5 (enExample)
JP2012522056A5 (enExample)
JP2009506039A5 (enExample)